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Background: Since the definition of different histologic subtypes of urothelial carcinomas by the World Health
Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has
gained more attention.
Methods: We reviewed 205 tumor samples of patients with locally advanced bladder cancer mainly treated within
the randomized AUO-AB05/95 trial with radical cystectomy and adjuvant cisplatin-based chemotherapy for
histologic subtypes. 178 UC, 18 plasmacytoid (PUC) and 9 micropapillary (MPC) carcinomas of the bladder were
identified. Kaplan Meier analysis and backward multivariate Cox’s proportional hazards regression analysis were
performed to compare overall survival between the three histologic subtypes.
Results: Patients suffering from PUC have the worst clinical outcome regarding overall survival compared to
conventional UC and MPC of the bladder that in turn seem have to best clinical outcome (27.4 months, 62.6
months, and 64.2 months, respectively; p=0.013 by Kaplan Meier analysis). Backward multivariate Cox´ s proportional
hazards regression analysis (adjusted to relevant clinicopathological parameters) showed a hazard ratio of 3.2
(p=0.045) for PUC in contrast to patients suffering from MPC.
Conclusions: Histopathological diagnosis of rare variants of urothelial carcinoma can identify patients with poor
prognosis.
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Urothelial carcinoma (UC) is one of the most common
malignancies with a total of 110,500 new cases diagnosed
per year in Western Europe [1]. The plasmacytoid urothe-
lial carcinoma of the bladder (PUC) and the micropapil-
lary carcinoma of the bladder (MPC) represent two of
several rare variants of urothelial carcinoma, which were
included in the World Health Organisation (WHO) classi-
fication in 2004 [2]. Each of these subtypes accounts for
approximately 3-5% of UC in patients with muscle* Correspondence: bastian.keck@uk-erlangen.de
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reproduction in any medium, provided the orinfiltration. Morphologically, PUC presents with a disco-
hesive, single cell growth pattern, with eccentrically
located nuclei and an abundant eosinophilic cytoplasm
(Figure 1) [3]. PUC is usually diagnosed at an advanced
pathological stage and survival appears to be more
unfavourable to what has been described for conventional
UC [4]. MPC was first described by Amin et al. in 1994
[5] and is characterised by medium sized cells surrounded
by an eosinophilic cytoplasm with an irregular distribution
of chromatin, frequent mitotic figures and nuclear pleo-
morphisms [5-8]. Because of this original identification,
multiple reports describing the aggressive biologic beha-
viour of MPC and its unfavourable clinical course, in
mainly small cohorts, have been published. Clinical datad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Hematoxylin and eosin staining (200x): Plasmacytoid
urothelial carcinoma showing a characteristic single cell growth
pattern with eccentrically located nuclei and abundant
eosinophilic cytoplasm.
Figure 2 Hematoxylin and eosin staining (200x): Micropapillary
carcinoma with medium sized tumor cells and eosinophilic
cytoplasm that typically arrange in small nests and show slender,
delicate processes, often with a central fibrovascular core.
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on survival of patients treated with cystectomy and
an adjuvant cisplatin-based chemotherapy are still
lacking. Thus, we describe for the first time the clinical
behaviour of MPC and PUC in comparison to UC in
patients treated with cystectomy and adjuvant
cisplatin-based chemotherapy within the prospective
and randomized trial AUO-AB05/95.
Methods
For this study 221 tissue samples of patients suffering
from locally advanced bladder cancer were analysed. Of
the 205 patients, 166 tissue samples from the AUO-AB05/
95 trial comparing methotrexate, vinblastine, epirubicin,
and cisplatin (M-vec) (80 patients) and cisplatin plus
methotrexate (Cm) (86 patients) were available. These
patients were randomly assigned to the therapy. 39
patients with locally advanced bladder cancer were treated
with radical cystectomy and adjuvant chemotherapy with
gemcitabine, cisplatin (Gc) according to current guidelines
were added to analysis, None of the patients received
neoadjuvant chemotherapy. The study protocol of the
AUO-AB 05/95 trial was approved by the committee of
the “Arbeitsgemeinschaft Urologische Onkologie” of the
German Cancer Society and the local ethics committees
of the participating centers. All tissue samples were
obtained with approval of the ethical committee of the
Friedrich-Alexander-University Erlangen-Nuremberg. For
this paper histological workup of tissue samples of radical
cystectomy from these patients was done retrospectively
from large sections by an experienced uropathologist
(AH) to identify the histologic subtypes of muscle invasive
bladder cancer including determination of the histological
type. Tumors were defined as variant histology (PUC andMPC) if they showed at least 50% of the specific histology.
Squamous cell carcinomas, nested-type carcinomas
and small cell carcinomas were excluded from ana-
lysis. Grading was performed according to the WHO
classification of 1973 and the one of 2004. The study
population and details of the AUO-05/95 trial have
been reported previously [9]. In addition to 178 UC
cases, 18 PUC (Figure 1) and 9 MPC (Figure 2) cases
were identified. A Kaplan Meier analysis and a multi-
variate Cox’s proportional hazards regression analysis
were performed to compare overall survival between
the three histologic subtypes. Statistical tests were
performed using the IBM SPSS Statistics 19 software.
All of the tests were two-sided, and a P value <0.05 was
regarded as statistically significant (IBM SPSS, Chicago, IL,
USA). Correlations between the histological subtypes and
the clinicopathological parameters were determined with
the Fisher’s exact test but between them and age with the
t-test. Correlations between overall survival and histo-
logical subtypes were studied univariately with a Kaplan
Meier analysis (log rank test) and multivariately with a
Cox’s regression hazard analysis (adjusted to age, sex,
tumor grade, tumor stage, lymph node and metastases
status, type of chemotherapy).
Results
Clinicopathological parameters of the included patients
are shown in Table 1. Although a limited number of
patients were included from the MPC and PUC tumor
types, they appear to be more frequent in male patients
than in female patients (UC: 3.3:1, PUC: 8:1, MPC 9:0).
The mean age of the PUC patients seemed to be somewhat
lower than that of patients suffering from UC or MPC
(57.9, 61.0, and 62.3 years, respectively, p= 0.057). A
Table 1 Comparison of clinicopathological parameters of conventional UC, PUC and MPC urothelial carcinomas treated
with radical cystectomy and adjuvant cisplatin based chemotherapy
Total UC PUC MPC P-Value*
Age 0.057**
Range 29-75 29-75 46-70 56-70
Mean 60.9 61.0 57.9 62.3
Median 61.7 61.9 59.3 60.8
Gender 205 178 18 9 0.116
Female 45 (22%) 43 (24%) 2 (11%) 0 (0%)
Male 160 (78%) 135 (76%) 16 (89%) 9 (100%)
pT 205 178 18 9 0.168
pT1 5 (2,5%) 5 (3%) 0 (%) 0 (0%)
pT2 22 (11%) 19 (11%) 3 (17%) 0 (0%)
pT3 142 (69%) 125 (70%) 13 (72%) 4 (45%)
pT4 36 (17.5%) 29 (16%) 2 (11%) 5 (55%)
Grade (1973) 205 178 18 9 0.263
Grade 2 22 (11%) 22 (12%) 0 (0%) 0 (0%)
Grade 3 183 (89%) 156 (88%) 18 (100%) 9 (100%)
Grade (2004)
Low-grade 0% 0% 0% 0%
High-grade 100% 100% 100% 100%
pN 205 178 18 9 0.743
pN0 90 (44%) 80 (45%) 6 (33%) 4 (44.4%)
pN1 45 (22%) 40 (22.5%) 3 (17%) 2 (22.2%)
pN2 69 (33.5%) 57 (32%) 9 (50%) 3 (33.3%)
pN3 1 (0.5%) 1 (0.5%) 0 (0%) 0 (0%)
pM 205 178 18 9 1.000
pM0 204 (99.5%) 177 18 (100%) 9 (100%)
pM1 1 (0.5%) 1 0 (0%) 0 (0%)
Chemotherapy 205 178 18 9 0.043
Gc 39 39 (%) 0 (0%) 0 (0%)
M-vec 80 64 (%) 11 (61%) 5 (55%)
Cm 86 75 (%) 7 (39%) 4 (45%)
Survival 205 178 18 9 0.061
Alive 120 109 6 (33.3%) 5 (55%)
Dead 85 69 12 (66.6%) 4 (45%)
Abbreviations: Gc - Gemcitabine, cisplatin, M-vec - Methotrexate, vinblastine, epirubicin and cisplatin, Cm – Cisplatin, methotrexate.
* statistical test: Fisher’s exact test.
** statistical test: t-test.
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the different histotypes (P=0.043; Fisher’s exact test;
Table 1) is detected. This difference is reasoned by the fact
that only UC patients but not MPC or PUC patients have
been treated with gemcitabine and cisplatin. However,
when we consider only M-vec and Cm treatment regimens
no significant difference between the different histotypes is
detected (P=0.451; Fisher’s exact test; data not shown).Overall survival of PUC patients was significantly
worse than that of patients suffering from UC or
MPC (27.4 months with 95% CI: 16.8-37.9 months,
62.6 months with 95% CI: 54.8-70.4 months, and
64.2 months with 95% CI: 41.9-86.4, respectively;
p=0.013 using Kaplan Meier analysis; Figure 3). A
backward multivariate Cox´ s proportional hazards regres-
sion analysis including clinicopathological parameters
Figure 3 Kaplan-Meier analysis: Correlation of histology
subtype with overall survival. Patients with a plasmacytoid
urothelial cancer (lower curve, N=18) showed with 27.4 months
(range: 16.8-37.9) the shortest overall survival, patients with a
conventional UC (middle curve, N=178) survived in average 62.6
months (range: 54.8-70.4) whereas patients with a micropapillary
urothelial cancer possessed the longest average survival with 64.2
months (range: 41.9-86.4; upper curve N=9). The mean survival was
significantly different between patients with plasmacytoid urothelial
cancer and those with micropapillary urothelial cancer (P=0.013; log
rank test). Censoring of patients (marked with a cross) means
mathematically removing a patient from the survival curve at the
end of his/her follow-up time.
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metastases status, type of chemotherapy) showed a
hazard ratio of 3.2 (95% CI: 1.0-9.9; p=0.045) for PUC in
contrast to patients suffering from MPC (Table 2 and
Figure 4). When we analyzed the hazard ratio of the
PUC patients compared with the UC patients with the
same backward model we still see a 2.4-fold (95% CI:
1.3-4.4; p=0.006) increased risk of death for the PUC
patients but no significant difference in risk of death be-
tween UC and MPC patients was seen (data not shown).
The lymph node status was only in the first step sig-
nificantly associated with the risk of death but at further
backward steps only a trend towards significance was
observed (Table 2).
At considering that we do not have for all patients the
information for cancer-associated death we calculated
their cancer-associated risk of death. In Kaplan Meier
analysis we detected mean cancer-associated survival
rates for PUC patients of 35.5 months, for UC patients
of 67.8 months and for MPC patients of 64.2 months
but this is not significant (P=0.22, log rank test). In themultivariate Cox’s regression hazard analysis a 2.0-fold
increased risk of tumor-related death for PUC patients
compared to MPC patients was found but it was not sig-
nificant (P=0.26) and an 1.8-fold increased risk of
tumor-related death for PUC patients compared to UC
patients what was again not significant (P=0.15).
Discussion
Systemic cisplatin-based chemotherapy is regarded as
the therapy of choice in metastatic UC. However, the
role of adjuvant or neoadjuvant chemotherapy remains
under debate [10,11]. Most urological and oncological
guidelines recommend neoadjuvant cisplatin-based che-
motherapy as the therapy of choice in locally advanced
bladder cancer [12]. Because the description of several
rare variants of UC of the bladder in the WHO clas-
sification of 2004, descriptions of their clinical course
and the molecular features have become more prevalent.
However, despite improved knowledge regarding the
molecular characteristics of the histologic subtypes of
bladder cancer, the impact of these differences on sys-
temic therapies is lacking. Most patients with locally
advanced UC are treated without regard to the under-
lying histology, although it has been reported that
tumors with variant histology are associated with a
higher risk of progression than conventional high grade
UC [13]. As for PUC we could show in the largest series
described to date, that on the one hand this subtype of
UC accumulates prognostic unfavourable molecular fea-
tures, like such as the loss of CK20, a high proliferation
index and p53 accumulation, and as well as on the other
hand exhibits characteristic molecular features, like such
as a complete loss of membranous E-cadherin expres-
sion [4]. Moreover, our results from this study demon-
strate that patients suffering from PUC are of younger
age than those suffering from UC or MPC. However,
therapeutic strategies with radical cystectomy and
cisplatin-based chemotherapy does not seem to be as
effective for PUC as it is described for locally advanced
UC or MPC, even though the number of patients is
limited and may serve as a bias. As it was reported
recently, a complete response to adjuvant chemotherapy
administering M-VEC and neoadjuvant chemotherapy
using gemcitabine and cisplatin may occur at least in a
subgroup of PUC -patients [14]. Therefore, chemothe-
rapy in a neoadjuvant or adjuvant setting should be part
of the therapeutic considerations. In the present study,
we could not confirm these results in our analysis of ad-
juvant cisplatin-based chemotherapy with a median
overall survival of 27.4 months, which is approximately
half of that observed in the patients suffering from con-
ventional locally advanced UC (Kaplan-Meier analysis).
Thus, PUC tumor biology represents a negative prog-
nostic factor for patients suffering from this histologic
Table 2 Backward Cox’s proportional hazards regression analysis
Variables in the equationb
B SE Wald df Significance Exp
(B)
95.0% Confidence interval for Exp(B)
lower upper
Step 1 age -.151 .232 .422 1 .516 .860 .546 1.356
gender -.046 .281 .027 1 .870 .955 .550 1.657
pT .432 3 .933
pT(1) .146 .795 .034 1 .854 1.157 .244 5.495
pT(2) .047 .464 .010 1 .919 1.048 .422 2.602
pT(3) .185 .307 .364 1 .546 1.203 .659 2.196
Grade .301 .351 .733 1 .392 1.351 .679 2.690
pN -.468 .239 3.842 1 .050 .626 .392 1.000
M . 0a .
Adjuvant Chemo 2.790 2 .248
Adjuvant Chemo(1) -.359 .538 .446 1 .504 .698 .243 2.005
Adjuvant Chemo(2) .313 .233 1.806 1 .179 1.368 .866 2.160
Histo subtype 7.017 2 .030
Histo subtype(1) 1.095 .588 3.463 1 .063 2.988 .943 9.466
Histo subtype (2) .261 .535 .237 1 .626 1.298 .455 3.703
Step 3 age -.148 .221 .446 1 .504 .863 .559 1.331
gender -.078 .275 .081 1 .776 .925 .539 1.585
Grade .270 .335 .650 1 .420 1.310 .679 2.528
pN -.436 .226 3.737 1 .053 .646 .415 1.006
Adjuvant Chemo 2.621 2 .270
Adjuvant Chemo(1) -.360 .538 .448 1 .503 .697 .243 2.002
Adjuvant Chemo(2) .294 .229 1.642 1 .200 1.342 .856 2.103
Histo subtype 7.587 2 .023
Histo subtype(1) 1.150 .581 3.920 1 .048 3.157 1.012 9.852
Histo subtype(2) .298 .523 .325 1 .569 1.348 .483 3.759
Step 4 age -.152 .221 .474 1 .491 .859 .558 1.324
Grade .270 .336 .649 1 .421 1.310 .679 2.529
pN -.437 .226 3.743 1 .053 .646 .415 1.006
Adjuvant Chemo 2.576 2 .276
Adjuvant Chemo(1) -.375 .535 .490 1 .484 .687 .241 1.963
Adjuvant Chemo(2) .285 .227 1.576 1 .209 1.330 .852 2.075
Histo subtype 7.516 2 .023
Histo subtype(1) 1.155 .580 3.959 1 .047 3.173 1.017 9.895
Histo subtype(2) .317 .519 .372 1 .542 1.373 .496 3.797
Step 5 Grade .292 .333 .766 1 .381 1.339 .697 2.574
pN -.420 .224 3.522 1 .061 .657 .423 1.019
Adjuvant Chemo 2.442 2 .295
Adjuvant Chemo(1) -.358 .535 .449 1 .503 .699 .245 1.993
Adjuvant Chemo(2) .278 .226 1.506 1 .220 1.320 .847 2.056
Histo subtype 7.388 2 .025
Histo subtype(1) 1.144 .580 3.890 1 .049 3.141 1.007 9.792
Histo subtype (2) .315 .519 .368 1 .544 1.370 .496 3.787
Keck et al. BMC Cancer 2013, 13:71 Page 5 of 8
http://www.biomedcentral.com/1471-2407/13/71
Table 2 Backward Cox’s proportional hazards regression analysis (Continued)
Step 6 pN -.434 .223 3.771 1 .052 .648 .418 1.004
Adjuvant Chemo 2.328 2 .312
Adjuvant Chemo(1) -.399 .532 .561 1 .454 .671 .237 1.905
Adjuvant Chemo(2) .256 .224 1.298 1 .255 1.291 .832 2.004
Histo subtype 6.980 2 .030
Histo subtype (1) 1.145 .580 3.896 1 .048 3.143 1.008 9.800
Histo subtype(2) .357 .516 .478 1 .489 1.429 .520 3.928
Step 7 pN -.404 .222 3.307 1 .069 .667 .432 1.032
Histo subtype 8.123 2 .017
Histo subtype (1) 1.162 .580 4.015 1 .045 3.197 1.026 9.964
Histo subtype (2) .302 .515 .344 1 .558 1.352 .493 3.709
a. Degree of freedom is reduced because of constant or linear dependent covariates.
b. Constant or linear dependent covariate M = 1; Significant values are marked in bold face.
Exp(B) equals relative risk value (RR).
Abbreviations and further information.
Age: was grouped in group1 ≤ 60years and group 2 > 60 years.
Gender: female (reference) and male groups.
pT: tumor stage; pT(1)-tumor stage 1: pT(2) tumor stage 2; pT(3): tumor stage 3; (tumor stage 4 is reference).
Grade: tumor grade: tumor grade 2 and tumor grade 3 (reference).
pN: lymph node status, was grouped in group1=N0 and group2=N≥1 (N1, N2, N3, reference group).
M: metastates status, group1without metastases (M0) and group 2 with metastases (M1), only one patient in group 2 therefore no calculations were performed.
Adjuvant Chemo: Adjuvant Chemotherapy in 3 groups: Adjuvant Chemo(1) is treated with Gc = Gemcitabine, Cisplatin, Adjuvant Chemo(2) is treated with
M-vec = Methotrexate, Vinblastine, Epirubicin, Cisplatin and the group treated with CM = Cisplatin, Methotrexate is the reference group.
Histo subtype: Histology subtypes in 3 groups: Histo subtype(1) is the plasmacytoid urothelial carcinoma patients’ group, Histo subtype(2) is the conventional
urothelial carcinoma patients’ group and the group with the micropapillary urothelial carcinoma patients is the reference group.
Figure 4 Multivariate Cox’s regression hazard analysis
(adjusted to age, sex, tumor grade, tumor stage, lymph node
and metastases status, type of chemotherapy): Correlation of
histology subtype with overall survival. Patients with a
plasmacytoid urothelial cancer (lower curve; N=18) have a 3.2-fold
(95% CI: 1.0-9.9; P=0.045) increased risk of death while patients with
conventional UC (middle curve; N=178) have a 1.3-fold (95% CI: 0.5-3.7;
P=0.558) but not significant increased risk of death compared with
patients with a micropapillary urothelial cancer (upper curve, N=9).
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mesenchymal transition (EMT) and upregulation of
transcriptional repressors of E-cadherin may contribute
to the aggressiveness of these tumors and a possibly
reduced sensitivity to chemotherapeutic agents [4,15,16].
Micropapillary carcinomas have been described in dif-
ferent tumor entities, such as colorectal, breast, lung and
others [17-19]. Thus, immunohistochemical panels for
discriminating micropapillary tumors of different origins
have been reported previously. Within this broad
molecular panel, CK20 and uroplakin are the best
molecular markers to determine urothelial origin of
MPC [19]. In MPC, the initial molecular data explaining
their unfavourable clinical course were recently identi-
fied, with HER2/neu gene amplification, amongst others,
as a frequent molecular alteration in this variant [20].
Clinical reports suggest these are markers of biologically
aggressive carcinoma with frequent lymphatic vessel
invasion in TURB specimens and lymph node metastasis
[6,8,21]. Moreover, clinical upstaging to locally advanced
diseases occurs in the vast majority of the cases and repre-
sents a problem in planning therapeutic strategies [22]. In
response, Compérat et al. highlighted the importance of
adequate tumor sampling, including analysis of the
detrusor muscle, to avoid possible upstaging. Moreover,
they state that due to the associated aggressive behaviour,
the proportion of micropapillary differentiation should be
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10% of the specimen, as it has prognostic relevance
[22]. Additionally, inter-observer reproducibility of the
diagnosis of MPC is low [23], which may lead to
treatment delays or the use of inappropriate therapeutic
strategies adversely affecting patients’ survival. Therefore,
pathologists should be aware of the histologic subtypes on
diagnosis. Furthermore, urologists or oncologists should
take this information into account when planning surgical
or chemotherapeutic treatment options. Supporting the
recommendations of Compérat and coworkers Kamat
et al. postulated that even papillary and non-invasive MPC
should be treated by radical cystectomy to prevent
progression and systemic disease [22,24]. In their analysis
they demonstrated that neoadjuvant cisplatin-based
chemotherapy did not result in an improved 5-year overall
survival and that intravesical immunotherapy using BCG
was not effective in this histologic variant [24]. Most
studies on MPC describe poor disease-specific survival
following adjuvant chemotherapy [8,20,25]. However, our
data are in contrast to the experiences reported previously.
We demonstrated that the survival rates were comparable
for MPC and UC if treated with radical cystectomy and
adjuvant chemotherapy. These contradictory results may
be explained by the prospective randomized nature in
which the patients were recruited and included only upon
the ability to compare UC, MPC and PUC within a single
trial. Although the relatively low number of patients suf-
fering from MPC or PUC may limit the value of our study,
it provides important information regarding their clinical
course and the aggressive biology of the tumor subtypes.
A possible limitation of our study might be the interobser-
ver variability in defining histological subtypes as there is
still no consensus on the optimal cut off value of variant
histology in the specimen to define PUC or MPC. Another
limitation of our results is the measurement of overall sur-
vival in our series as this could be affected by several vari-
ables besides tumor characteristics. However, on the other
hand chemotherapy can have effects on comorbidity and
therefore finally affect overall survival what is of relevance
for the patients. Awareness of these different bladder
cancer variants appears to be crucial when analyzing
the molecular characteristics of advanced bladder
cancers and when tailoring personalized therapeutic
procedures in the future.
Conclusion
The specific tumor histology gives important prognostic
information of patients suffering from locally advanced
bladder cancer treated by radical cystectomy and adjuvant
chemotherapy. Our results implicate that determining the
exact pathological diagnosis, including the description of
histologic subtypes of bladder cancers according to the
WHO classification of 2004, are important. As UC, PUCand MPC are associated with a different clinical course if
treated with cystectomy and adjuvant cisplatin-based
chemotherapy prospective multicenter studies, comparing
the different histologic variants of bladder cancer and
their molecular features are necessary to tailor therapeutic
strategies in the future. Furthermore, a joint study inclu-
ding the collection of rare bladder cancers is strongly
warranted with a goal of enforcing additional molecular
studies for the identification of potential prognostic and
therapeutic targets.
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